Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses

A technology of hepatitis C virus and hepatitis C, which is applied in the field of medicine and can solve problems such as the application of artemisinin and its derivatives to hepatitis C virus.

Inactive Publication Date: 2012-10-31
WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no application of artemisinin and its derivatives in anti-HCV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses
  • Application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses
  • Application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Embodiment 1: the evaluation of artemisinin and derivative thereof anti-hepatitis C virus activity

[0051] A kind of application of artemisinin and its derivatives in the preparation of medicine for treating hepatitis C virus (HCV), the steps are:

[0052] 1. Experimental materials

[0053] 1.1 Cells, plasmids, viruses and drugs

[0054]Huh7.5.1 cells were donated by Dr.F.V.Chisari (please refer to the table of genetic resources); the plasmid pJFH1 containing the complete genome sequence of HCV type 2a JFH1 strain was donated by Prof. Dr. Takaji Wakita (please refer to the table of genetic resources). The virus JFH1-5AGFP with reporter gene was prepared by our laboratory; artemisinin, dicyanide artemisinin, artemether and artesunate were purchased from sigma company.

[0055] 1.2 Reagents

[0056] DMEM medium was purchased from GIBCO Company; MTT detection reagent was purchased from biomol Company; restriction endonuclease was purchased from NEB Company.

[0057] 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of artemisinin and derivatives thereof in preparation of medicaments for treating hepatitis C viruses (HCV). The medicaments which almost do not have toxic concentration are used for anti-virus test; and by detecting the influence of the artemisinin and the derivatives thereof such as dicyanogen artemisinin, artemether and artesunate on HCV replication, the artemisinin and the derivatives thereof serving as small molecular compounds have remarkable viral activity resistance and are dose-dependent. The artemisinin and the derivatives thereof which have already been used for clinical antimalarials have low toxic or side effect on a human body. The artemisinin and the derivatives thereof which almost do not have toxicity can inhibit about 90 percent of HCV replication, and are efficient and low-toxic anti-HCV compounds. The compounds have a broad prospect for developing anti-HCV medicaments.

Description

technical field [0001] The invention belongs to the technical field of medicine, and more specifically relates to the application of artemisinin and its derivatives in the preparation of medicines for treating hepatitis C virus (HCV). Background technique [0002] Hepatitis C virus (Hepatitis C Virus, HCV) was discovered in 1989, it is the main pathogen causing non-A non-B hepatitis after blood transfusion. About 170 million people worldwide are currently infected with HCV. HCV infection is distributed worldwide, with an infection rate of about 3%, of which 3 to 4 million new cases are added each year. According to the serological epidemiological survey data in my country, the positive rate of HCV in the general population is 3.2%. The main routes of transmission of HCV include blood transfusion or blood products, intravenous drug use, sexual contact, and mother-to-child transmission. HCV infection can easily lead to chronicity, and only about 20% of HCV-infected patients...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/366A61K31/357A61P1/16A61P31/14
Inventor 陈绪林曾晶廖庆姣吴阳
Owner WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com